• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Building Britain into a Scientific Superpower…
Mar 3 2021

The ‘o2h Ventures Human Health Knowledge Intensive fund’ is the only HMRC approved fund in the world that is singularly focused on investing into British early stage biotech therapeutics.

When Rishi Sunak, the Right Honorable Chancellor delivered his budget speech he referred to Britain’s aspiration to be a ‘Scientific Superpower’. At o2h Ventures we have reviewed and evaluated a significant number of innovative businesses over the last 2 years and we have made investments into around 35 companies*. We can concur that Britain has the potential to be a ‘Scientific Superpower’; we have world-class scientists and infrastructure along with strong academic grass roots. With the appropriate government intervention through further tax incentives, amending IPO listing rules in London, unlocking pensions for investing, and management training for our scientists, will only go to further make this a more attractive sector for investments. Mr Sunak announced a review today and judging by his tone and ambition the changes will only be positive for the Biotech sector; we are already excited given the tailwind that we have had during the pandemic.

Our Flagship ‘Human Health KI Fund’ will close on March 31st 2021 and can provide significant tax benefits**, which can be carried back to the 2019/21 tax year, due to our HMRC approved status. Please register at www.o2hventures.com for further information and/or download the Hardman & Co independent report at https://o2hventures.com/download-o2hventures-hardman-co-rep

We believe our investment focus has allowed us to access, understand (through a deepdive technical due diligence) and invest tax efficiently via EIS into some very exciting companies.

Exonate, A Nottingham University spinout developing a drug for wAMD/Macular Degenerative Disease – announced a significant collaboration with Janssen (Johnson & Johnson) and are now dosing their first patients in Australia. Having invested into this company and holding the Chair position, we are very excited to see the results!
https://www.exonate.com

Small Pharma, developing a Psychedelic drug as a novel depression treatment. Phase I/IIa clinical trials are approved. The company announced plans to go public through a reverse merger with Capital Pool Company, Unilock, aiming to enter Canada’s TSXV exchange. The price per share planned is a significant uplift on our investment and should complete early April 2021.
https://www.smallpharma.co.uk

Oxford Drug Design, developing an antibiotic, received ~$11M of non-dilutive funds (milestone based). Driving from the Board, o2hVentures has supported the company through the ‘academic’ phase and now the company has appointed a CEO to lead the company through the next phase.
https://oxforddrugdesign.com

Turbine, An AI platform for cancer drugs targeting the DNA Damage Response pathway. Post our Seed investment, the company has announced a further USD 6.85m, in investment. The transatlantic round was led by new investor Accel and included XTX Ventures and Boston Millennia Partners. https://turbine.ai

In4Derm, recent investment into a University of Dundee spin-out, developing both topical and oral therapies for Psoriasis and other inflammatory conditions. Within a few months of o2h leading and completing the investment, the company has experienced significant real commercial interest in a collaboration.
https://www.in4derm.co.uk

Metrion Biosciences, a Cambridge based service company with deep expertise in ion- channels. Prior to the previous o2h Ventures led round the company was unprofitable and now despite Covid disruptions in operations the company is EBITDA positive. The company is in the final stages of a further sizable investment from an established VCT.
https://www.metrionbiosciences.com

AIVIVO – utilises its AI platform and suggested potential therapies for COVID-19.
http://www.aivivo.co

Our full portfolio of investments can be seen at https://o2hventures.com/portfolio.
If we can provide you with any further detail or information please email us at invest@o2h.com

The Team at o2h Ventures
* These investments are from Prashant and Sunil as Business Angels earlier and more recently from the o2h Ventures fund.
**Please refer to the Information memorandum for more details on tax relief and the conditions for claiming the tax relief that depends on individual circumstances. Capital at risk.

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science 28 Feb 2023
  • o2h-ventures Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 Jan 2023
  • o2h-ventures o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 Jan 2023

Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.

Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023
  • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023
  • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
This website is a financial promotion approved by o2h Ventures Ltd for the purposes of section 21 Financial Services and Markets Act 2000 relating to the communication of invitations or inducements to engage in investment activity. o2h ventures Limited is regulated and authorised by the Financial Conduct Authority. The FCA firm reference number is 812245 and further information can be found on the Financial Services Register.

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)